<< Back to News

System Formulary Update
Contraceptives Class Standardization

Situation:

Contraceptives – Oral Progestins and Estrogen/Progestin Combinations class review standardization was approved for addition to the health system formulary at the September 2023 System Pharmacy and Therapeutics Committee Meeting.

Background:

The following products were reviewed: drospirenone 3 mg-ethinyl estradiol 0.02 mg tablet, levonorgestrel-ethinyl estradiol 0.1 mg-20 mcg tablet, norethindrone 0.5 mg-ethinyl estradiol 35 mcg tablet, norethindrone 1 mg-ethinyl estradiol 35 mcg tablet, norethindrone-e. estradiol triphasic 0.5 mg/0.75 mg/1 mg- 35 mcg tablet, norgestimate-ethinyl estradiol triphasic 0.18 mg/0.215 mg/0.25 mg- 35 mcg tablet, norgestrel 0.3 mg-ethinyl estradiol 35 mcg tablet, norgestrel 0.3 mg-ethinyl estradiol 50 mcg tablet, norethindrone 0.35 mg tablet, norgestimate 0.25 mg- ethinyl estradiol 35 mcg tablet, and norethindrone 1 mg-ethinyl estradiol 20 mcg-iron 75 mg tablet.

Assessment/Recommendations:

System P&T voted to include the following product from the UNC Health Medication Formulary:

• Norethindrone 0.35 mg tablet
• Norgestimate 0.25 mg- ethinyl estradiol 35 mcg tablet
• Norethindrone 1 mg-ethinyl estradiol 20 mcg-iron 75 mg tablet

Note: Stock of this formulary product may vary at individual entities 

Formulary/Epic Changes will Go-Live on Tuesday, December 5, 2023